Rapport Therapeutics, Inc.

Rapport Therapeutics, Inc. (RAPP) priced its initial public offering on Jun 7, 2024 at $17.00 per share, raising $136M, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $601.4M. Goldman Sachs was lead-left underwriter, joined by Jefferies, TD Cowen and Stifel. Goodwin Procter advised the company and Cooley advised the underwriters.

Rapport Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing small molecule medicines for central nervous system disorders. Its most advanced product candidate, RAP-219, is an AMPA receptor negative allosteric modulator.

Status

IPO

Ticker

RAPP

Exchange

Nasdaq Global Market

Priced

Jun 7, 2024

IPO price

$17.00

Raised

$136M

Market cap at IPO price

$601.4M

First filed

May 17, 2024

Underwriters

Goldman Sachs, Jefferies, TD Cowen and Stifel

Company counsel

Goodwin Procter

Underwriters' counsel

Cooley

Sector

Biotech & pharma

Country / state

MA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.